Article
Multidisciplinary Sciences
Jun-Ki Moon, Jung Il Lee, Kyu-Tae Hwang, Jae-Hyuk Yang, Ye-Soo Park, Ki-Chul Park
Summary: This study compared the fixation stability and mechanical characteristics of basicervical femoral neck fractures fixed using FNS and DHS, showing no significant differences and suggesting that FNS fixation may provide biomechanical stability comparable to DHS for treating such fractures in young adults.
SCIENTIFIC REPORTS
(2022)
Article
Endocrinology & Metabolism
Socrates Papapoulos, Henry Bone, Felicia Cosman, David W. Dempster, Michael R. McClung, Toshitaka Nakamura, Jose Fernando Molina Restrepo, Mary L. Bouxsein, Dosinda Cohn, Anne de Papp, Rachid Massaad, Arthur Santora
Summary: This study prospectively assessed femur fractures in women at increased fracture risk during treatment with the cathepsin K inhibitor, odanacatib (ODN), and found that the rates of hip and ST/FS fractures were lower in the ODN group compared to the placebo group, but low-energy ST/FS fractures were more frequent in ODN-treated women. The results provide insight into possible pathogeneses of atypical femur fractures, suggesting a need to reconsider the current diagnostic criteria.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Article
Multidisciplinary Sciences
Yang Li, Dong Sun, Kelai Wang, Jingwei Liu, Zhe Wang, Yu Liu
Summary: This study aimed to evaluate the relevant factors of postoperative avascular necrosis of the femoral head (AVN) in children with femoral neck fracture. The study found that there were significant differences in displacement degree and reduction quality in relation to the occurrence of AVN, while sex, age distribution, fracture classification, surgery timing, and mechanism of injury did not significantly differ. Logistic regression analysis showed that displacement degree was a relevant risk factor for AVN occurrence.
Article
Biochemistry & Molecular Biology
Kai Liu, Pengwei Jing, Zehan Liu, Ying Wang, Zhu Han, Youqiang Wang, Zhirui Zheng, Yue Wu, Tong Wang, Yuhui Li, Hongying Zhang, Lichun Wang
Summary: This study found that decreased serum levels of circulating irisin are associated with a high risk of osteoporosis-related hip fractures and osteoporosis.
Article
Orthopedics
Peter P. Hsiue, Zachary Tran, Clark J. Chen, Daniel Chiou, Peyman Benharash, Alexandra Stavrakis
Summary: This study compared the short-term complications between transplant and nontransplant patients who underwent hip arthroplasty for femoral neck fractures (FNFs). The study found that transplant patients had an increased risk of requiring blood transfusions, experiencing acute kidney injury, and being discharged to a medical facility compared to nontransplant patients. Among the transplant patients, there were no differences in short-term complications between those treated with hemiarthroplasty (HA) versus total hip arthroplasty (THA).
JOURNAL OF ARTHROPLASTY
(2022)
Article
Orthopedics
Jelena Jadzic, Slavisa Zagorac, Marija Djuric, Danijela Djonic
Summary: This study compared bone density and hip structure parameters between postmenopausal women with hip osteoarthritis and those with femoral neck fragility fracture. The results showed lower bone density in the femoral neck fracture group. The impact of hip osteoarthritis on hip structure displayed significant regional heterogeneity, with the intertrochanteric region showing the most notable difference.
INTERNATIONAL ORTHOPAEDICS
(2022)
Article
Endocrinology & Metabolism
Zora Messner, David Carro-Vazquez, Judith Haschka, Johannes Grillari, Heinrich Resch, Christian Muschitz, Peter Pietschmann, Jochen Zwerina, Matthias Hackl, Roland Kocijan
Summary: This study investigated circulating miRNAs as potential biomarkers for monitoring treatment response in women with postmenopausal osteoporosis on denosumab therapy. The results showed significant changes in expression of seven miRNAs after two years of treatment, which correlated with changes in bone mineral density and bone turnover markers.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Anna Wawrzyniak, Marzena Skrzypczak-Zielinska, Michal Michalak, Marta Kaczmarek-Rys, Alicja Ewa Ratajczak, Anna Maria Rychter, Kinga Skoracka, Michalina Marcinkowska, Ryszard Slomski, Agnieszka Dobrowolska, Iwona Krela-Kazmierczak
Summary: This study aimed to determine the influence of VDR gene variation on anti-osteoporotic one-year treatment with denosumab in Polish women with postmenopausal osteoporosis. The results showed that BB and Bb genotypes of the Bsml polymorphism of the VDR gene determine higher DXA parameter values both before and after one-year denosumab therapy in postmenopausal women with osteoporosis.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Anna Moilanen, Juho Kopra, Heikki Kroger, Reijo Sund, Toni Rikkonen, Joonas Sirola
Summary: This study monitored long-term changes in bone mineral density (BMD) in postmenopausal women over a 25-year period. It found that higher baseline BMD was associated with higher bone loss rate, while lower baseline BMI and greater BMI increase helped protect against postmenopausal bone loss. Hormone replacement therapy (HRT) users had lower bone loss compared to non-users.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Endocrinology & Metabolism
Anabela Barcelos, Judite Goncalves, Ceu Mateus, Helena Canhao, Ana Maria Rodrigues
Summary: This study reveals that non-hip osteoporosis-related fractures are common among post-menopausal women aged 50+ in Portugal, leading to excessive healthcare costs of over 74 million euros per year.
OSTEOPOROSIS INTERNATIONAL
(2023)
Article
Orthopedics
M. Tohidi, S. M. Mann, P. A. Groome
Summary: This study aimed to describe practice variation in the use of total hip arthroplasty (THA) for older patients with femoral neck fracture and to determine the association between patient, surgeon, and institution factors and treatment with THA. The strongest predictors for treatment of patients with femoral neck fracture with THA were patient age, treating surgeon, and treating institution.
BONE & JOINT JOURNAL
(2023)
Article
Medicine, General & Internal
Hao Zhu, Zheng Li, Yizhai Zhou, Rugeng Zheng, Cong Diao, Kepeng Li, Qi Feng
Summary: This study aims to explore the relationship between NLR and the severity of osteoporotic vertebral fractures and femoral neck fractures. The results show that NLR is significantly correlated with the severity of these fractures and is an independent risk factor for osteoporotic fractures.
Review
Medicine, General & Internal
Zhanglu Fang, Jianhua Cao, Xun Wang, Li Zhang
Summary: This case report highlights the importance of clinical symptoms and imaging examinations in diagnosing bilateral femoral neck stress fractures in elderly patients.
Article
Medicine, General & Internal
Shau-Huai Fu, Chen-Yu Wang, Chih-Chien Hung, Chia-Che Lee, Rong-Sen Yang, Chuan-Ching Huang, Chui-Jia Farn, Wei-Hsin Lin, Ho-Min Chen, Fei-Yuan Hsiao, Jou-Wei Lin, Chung-Yi Li
Summary: Discontinuation of denosumab resulted in an increased risk of major osteoporotic fractures, especially vertebral fractures. The increased risk tends to reveal within 1 year post-discontinuation and be greater after a longer treatment duration.
JOURNAL OF INTERNAL MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Yang Sun, Yue Li, Jiangbi Li, Xiaoping Xie, Feng Gu, Zhenjiang Sui, Ke Zhang, Tiecheng Yu
Summary: The study found that a combination treatment of teriparatide and denosumab in postmenopausal osteoporosis patients leads to greater increase in bone density compared to monotherapy, without significant difference in adverse events.
FRONTIERS IN PHARMACOLOGY
(2022)
Letter
Radiology, Nuclear Medicine & Medical Imaging
Brian Lentle, Jacques P. Brown, Linda Probyn, David Goltzman
CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION CANADIENNE DES RADIOLOGISTES
(2021)
Article
Orthopedics
Jacques P. Brown, Jonathan D. Adachi, Emil Schemitsch, Jean-Eric Tarride, Vivien Brown, Alan Bell, Maureen Reiner, Thiago Oliveira, Ponda Motsepe-Ditshego, Natasha Burke, Lubomira Slatkovska
Summary: This study found that the mortality rate was higher in adults aged over 65 after non-hip fractures caused by osteoporosis, especially within the first year post-fracture. The relative risk of mortality was 2.47 in women and 3.22 in men within 1 year post-fracture, with absolute mortality risk of 12.5% in women and 19.5% in men within one year post-fracture.
BMC MUSCULOSKELETAL DISORDERS
(2021)
Article
Endocrinology & Metabolism
Delphine Farlay, Sebastien Rizzo, Louis-Georges Ste-Marie, Laetitia Michou, Suzanne N. Morin, Shijing Qiu, Pascale Chavassieux, Roland D. Chapurlat, Sudhaker D. Rao, Jacques P. Brown, Georges Boivin
Summary: Bisphosphonates are commonly used drugs for treating osteoporosis, but long-term use may increase the risk of atypical femur fracture. Research found that patients with AFF had higher bone mineralization levels compared to non-AFF patients, potentially due to the accumulation of bisphosphonates in bone mineral affecting the osteocyte cytoskeleton.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Review
Obstetrics & Gynecology
M. R. McClung, A. L. Clark
Summary: Therapy to activate bone formation through osteoanabolic drugs can quickly increase bone mass and strength compared to anti-remodeling drugs. These drugs are more effective in women at high fracture risk, but have limited impact on bone loss during early menopause.
Article
Endocrinology & Metabolism
Emil Schemitsch, Jonathan D. Adachi, Jacques P. Brown, Jean-Eric Tarride, Natasha Burke, Thiago Oliveira, Lubomira Slatkovska
Summary: In this large retrospective cohort study, one in four patients experienced a subsequent hip fracture after any initial fracture, with the most common being hip fractures, occurring on average within 1.5 years. These findings emphasize the importance of early post-fracture interventions to reduce the risk of imminent hip fractures and the associated high costs.
OSTEOPOROSIS INTERNATIONAL
(2022)
Article
Endocrinology & Metabolism
Delphine Farlay, Sebastien Rizzo, David W. Dempster, Shuang Huang, Arkadi Chines, Jacques P. Brown, Georges Boivin
Summary: In postmenopausal women with osteoporosis, denosumab therapy for 10 years significantly increased bone mineralization, with more pronounced changes within the first 5 years. The study showed that denosumab treatment for 5 years led to a transition of mineral to more mature crystals and lower microhardness, indicating a persistence of low bone remodeling state at 5 and 10 years.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Endocrinology & Metabolism
Ron Goeree, Natasha Burke, Manon Jobin, Jacques P. Brown, Donna Lawrence, Bjorn Stollenwerk, Damon Willems, Ben Johnson
Summary: This study shows that romosozumab followed by alendronate is a cost-effective treatment option for postmenopausal women with osteoporosis at high risk for fracture in Canada. It is associated with reduced costs and greater benefit compared to alendronate and risedronate alone.
ARCHIVES OF OSTEOPOROSIS
(2022)
Article
Endocrinology & Metabolism
T. Oliveira, D. L. Kendler, P. Schneider, A. G. Juby, R. J. Wani, M. Packalen, S. Avcil, S. Li, C. Waters-Banker, E. Graves, S. McMullen, J. Brown
Summary: The study found that the rate of low-energy fractures slightly decreased in the first few months of the COVID-19 pandemic, while the rates of surgeries and surgical outcomes remained stable.
ARCHIVES OF OSTEOPOROSIS
(2022)
Article
Endocrinology & Metabolism
T. Oliveira, J. Brown, A. G. Juby, P. Schneider, R. J. Wani, M. Packalen, S. Avcil, S. Li, M. Farris, E. Graves, S. McMullen, D. L. Kendler
Summary: This study aimed to describe the care patterns for osteoporosis during the COVID-19 pandemic in Alberta, Canada, compared to the preceding three years. The study found a decline in healthcare resource utilization, physician visits, diagnostic and laboratory tests, and treatment initiations for osteoporosis during the pandemic. Despite an increase in telehealth visits, oral bisphosphonate treatment initiations remained lower than pre-pandemic levels.
ARCHIVES OF OSTEOPOROSIS
(2022)
Article
Medical Laboratory Technology
Jacques P. Brown, Andrew Don-Wauchope, Pierre Douville, Caroline Albert, Samuel D. Vasikaran
Summary: Bone turnover markers provide a dynamic assessment of bone remodeling, but are not useful in diagnosing osteoporosis or predicting bone loss and fractures. However, they have proven to be valuable in elucidating the pharmacodynamics and effectiveness of osteoporosis medications in clinical trials.
CLINICAL BIOCHEMISTRY
(2022)
Article
Endocrinology & Metabolism
Didier Hans, Enisa Shevroja, Michele McDermott, Shuang Huang, Min Kim, Michael McClung
Summary: The study evaluated the effect of denosumab on bone microarchitecture and found that it significantly improved bone microstructure in postmenopausal women with osteoporosis, independent of body mass index.
OSTEOPOROSIS INTERNATIONAL
(2022)
Article
Endocrinology & Metabolism
Anne R. Cappola, Richard J. Auchus, Ghada El-Hajj Fuleihan, David J. Handelsman, Rita R. Kalyani, Michael McClung, Cynthia A. Stuenkel, Michael O. Thorner, Joseph G. Verbalis
Summary: Multiple changes occur in various endocrine systems as individuals age. The understanding of age-related changes and their clinical management is developing. This statement reviews the current research in different endocrine axes and conditions specific to older individuals, including available therapies, clinical trials, key points, and scientific gaps. The goal is to inform future research to improve prevention and treatment strategies for age-associated endocrine conditions in older individuals.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Didier Hans, Michele McDermott, Shuang Huang, Min Kim, Enisa Shevroja, Michael McClung
Summary: Up to 10 years of denosumab treatment significantly improved bone microarchitecture in postmenopausal women with osteoporosis, independently of bone mineral density. The treatment also decreased the number of high fracture-risk patients and shifted more patients to lower fracture-risk categories.
OSTEOPOROSIS INTERNATIONAL
(2023)
Article
Endocrinology & Metabolism
Michael R. McClung, Donald Betah, Cynthia Deignan, Yifei Shi, Jen Timoshanko, Felicia Cosman
Summary: Romosozumab significantly reduced fracture risk and increased bone mineral density in women at high fracture risk.
ENDOCRINE PRACTICE
(2023)
Article
Endocrinology & Metabolism
Michael R. McClung, Michael A. Bolognese, Jacques P. Brown, Jean-Yves Reginster, Bente L. Langdahl, Yifei Shi, Jen Timoshanko, Cesar Libanati, Arkadi Chines, Mary K. Oates
Summary: Romosozumab, a monoclonal anti-sclerostin antibody, reduces fracture risk in postmenopausal women and transitioning to romosozumab after 12 months of denosumab treatment can improve lumbar spine BMD and maintain total hip BMD.